Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.13 USD | -0.13% | -4.14% | +7.43% |
Dec. 04 | Kenvue Inc. Presents at Morgan Stanley Global Consumer & Retail Conference, Dec-04-2024 11:45 AM | |
Nov. 20 | BNP Paribas Exane Lifts Price Target on Kenvue to $24 From $22 | MT |
Business description: Kenvue Inc.
- self care products (41,8%): for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.);
- personal care products (29.9%): primarily oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.);
- beauty and skin care products (28.3%): hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.).
Product marketing is assured through direct sales, distributors and the Internet.
Net sales are distributed geographically as follows: North America (49.3%), Europe-Middle East-Africa (21.9%), Asia-Pacific (20.1%) and Latin America (8.7%).
Number of employees: 22,000
Sales by Activity: Kenvue Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Self Care | 4.82B | 5.24B | 5.64B | 6.03B | 6.45B |
Essential Health | 4.9B | 4.78B | 4.87B | 4.57B | 4.62B |
Skin Health and Beauty | 4.61B | 4.45B | 4.54B | 4.35B | 4.38B |
Geographical breakdown of sales: Kenvue Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
North America | 6.51B | 7.1B | 7.28B | 7.42B | 7.61B |
Europe, Middle East, and Africa | 3.46B | 3.33B | 3.44B | 3.19B | 3.39B |
Asia-Pacific | 3.08B | 3.01B | 3.28B | 3.15B | 3.11B |
Latin America | 1.28B | 1.03B | 1.06B | 1.2B | 1.34B |
Managers: Kenvue Inc.
Director | Title | Age | Since |
---|---|---|---|
Thibaut Mongon
CEO | Chief Executive Officer | 54 | 2023-05-07 |
Paul Ruh
DFI | Director of Finance/CFO | - | 2023-04-30 |
Caroline Tillett
CTO | Chief Tech/Sci/R&D Officer | 52 | 2023-04-30 |
Bernardo Tavares
CTO | Chief Tech/Sci/R&D Officer | 56 | 2023-04-30 |
Meredith Stevens
COO | Chief Operating Officer | 61 | 2023-04-30 |
Members of the board: Kenvue Inc.
Manager | Title | Age | Since |
---|---|---|---|
Thibaut Mongon
BRD | Director/Board Member | 54 | 2023-05-07 |
Larry Merlo
CHM | Chairman | 68 | 2023-04-30 |
Vasant M. Prabhu
BRD | Director/Board Member | 64 | 2023-05-03 |
Richard Allison
BRD | Director/Board Member | 57 | 2023-05-07 |
Director/Board Member | 54 | 2023-05-07 | |
Melanie Healey
BRD | Director/Board Member | 63 | 2023-05-07 |
Betsy Holden
BRD | Director/Board Member | 68 | 2023-05-07 |
Michael Sneed
BRD | Director/Board Member | 65 | 2023-05-07 |
Tamara Franklin
BRD | Director/Board Member | 57 | 2023-05-07 |
Kathleen Pawlus
BRD | Director/Board Member | 64 | 2024-08-14 |
Company details: Kenvue Inc.
Group companies: Kenvue Inc.
Name | Category and Sector |
---|---|
McNeil AB
McNeil AB Pharmaceuticals: MajorHealth Technology McNeil AB operates within the consumer health care division that develops and manufactures medicines. It specializes in the manufacture of self-care medicines. The firm offers NICORETTE products for the global market. The company was founded in December 2006 and is headquartered in Helsinborg, Sweden. |
Pharmaceuticals: Major
|
Other Personal Products
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-0.13% | -4.14% | +14.68% | - | 44.35B | ||
+0.53% | -1.86% | +19.94% | +17.45% | 415B | ||
+0.03% | -0.66% | +22.80% | +18.92% | 147B | ||
+0.31% | -1.72% | +22.43% | +23.88% | 77.7B | ||
-0.35% | -0.48% | -3.19% | +7.65% | 69.13B | ||
+2.54% | +1.79% | -5.24% | +39.06% | 28.9B | ||
-1.41% | +5.69% | -40.86% | -76.69% | 28.06B | ||
+0.16% | +3.20% | +17.44% | +6.83% | 19.75B | ||
-0.75% | -0.74% | +18.94% | +39.33% | 15.03B | ||
+0.12% | -0.64% | -4.77% | -7.67% | 10.94B | ||
Average | +0.08% | -0.31% | +6.22% | +7.64% | 85.58B | |
Weighted average by Cap. | +0.18% | -1.26% | +15.28% | +14.82% |
Sector
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- KVUE Stock
- Company Kenvue Inc.